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Hepatitis C infection is a major public health concern globally. In Ireland, like other 
European countries, people who use drugs (PWUD) and prisoners carry a larger HCV disease 
burden than the general population. Recent advances in HCV management have made HCV 
elimination across Europe a realistic goal. Engaging these two marginalised and underserved 
populations remains a challenge. The aim of this review was to map key findings and identify 




A scoping review guided by the methodological framework set out by Levac and colleagues 




A total of 58 studies were identified and divided into the following categories; Epidemiology, 
Guidelines and Policy, Treatment Outcomes, HCV -related Health Issues and qualitative 
research reporting on Patients’ and Health Providers’ Experiences. This review identified 
significantly higher rates of HCV infection among Irish prisoners and PWUD than the 
general population. There are high levels of undiagnosed and untreated HCV infection in 
both groups. There is poor engagement by Irish PWUD with HCV services and barriers have 
been identified. Prison hepatology nurse services have a positive impact on treatment uptake 
and outcomes. Identified gaps in the literature include; lack of accurate epidemiological data 
on incident infection, untreated chronic HCV infection particularly in PWUD living outside 
Dublin and those not engaged with OST.  
 
Conclusion 
Ireland like other European countries has high levels of undiagnosed and untreated HCV 
infection. Collecting, synthesising and identifying gaps in the available literature is timely 




















Hepatitis C virus (HCV) infection is a major public health concern globally. In developed 
countries iatrogenic transmission of HCV has been substantially reduced and people who 
inject drugs (PWID) or have done so in the past are now the main group affected [1–5]. Of 
the 600,000 HCV infected people living in Europe an estimated 20,000-30,000 reside in 
Ireland [6–9]. An estimated 60% of HCV infections in Ireland remain undiagnosed [6, 10].  
Ongoing criminalisation of drug users ensure high levels of HCV in prison populations 
globally. It is estimated that a quarter of the global prison population have been exposed to 
HCV infection [11–13].  
Historically in Ireland, HCV transmission has occurred through infected blood and blood 
products with the majority of these infections occurring between the 1970s and the early 
1990s [14]. Prior to the introduction of routine screening of Irish blood donations (1991), 
approximately 1,700 people were infected through blood and blood products [6, 14]. HCV 
infection has been a notifiable disease in Ireland since 2004. Between 2004 and 2017, 14,107 
cases were notified by the diagnosing laboratory with a peak in 2007 (n=1,539) [15]. In 
recent years there has been a decrease in cases notified with the number of new cases 
stabilising [15]. In 2012, the case definition was altered to specifically exclude resolved cases 
of HCV infection which may explain part of the reduction in the number of cases notified 
after this date [6]. Although there were no notifications of HCV infection prior to 2004, 
diagnostic data from the National Virus Reference Laboratory (NVRL) estimates that 
approximately 10,000 individuals were diagnosed with HCV infection between 1989 and 
2004 [6]. A 2012 mathematical modelling study estimated the national prevalence of chronic 
hepatitis C in the Irish general population as 0.5-1.2% (20,000-50,000) [6]. A more recent lab 
based residual sera study reported a prevalence estimate of 0.5 % - 0.7% (20,000-30,000) [9]. 
Genotypes 1 and 3 are the types most commonly seen in Ireland and are distributed 55% and 
45% respectively [16]. These are estimates of prevalence and the true prevalence rate in 
Ireland is unknown. There is no general screening of the population to determine prevalence 
rates with most studies only assessing the prevalence within specific risk groups [17, 18]. 
 
The estimates of prevalence however do indicate that in the general population the prevalence 
of hepatitis C is low, and most cases are from a defined risk group mainly PWID, people who 
received unscreened blood or blood products and people who were born in hepatitis C 
endemic countries [10]. 
 
Hepatitis C related morbidity and mortality continues to increase in Ireland, with increased 
hospital admission for, HCV related end stage liver disease (ESLD), hepatocellular cancer 
(HCC) and liver transplant [10]. This increase is likely related to the fact that the peak 
incidence of HCV infection in Irish PWID was in the late 1990s, and those infected during 
this period are now developing ESLD or HCC [19].  
 
Since 2010 risk factor information has been available for 57% of notified chronic HCV cases 
in Ireland [6, 10, 14]. This data show injecting drug use (IDU) is the most common risk factor 
reported (80%), followed by possible sexual exposure (5%), receipt of blood or blood 
products (4%), vertical transmission (2%) and tattooing or body piercing (1%) (3). No risk 
factor was identified in 7% of notified cases [14].  
The most significant risk factor for the transmission of HCV infection in Ireland is through 
injecting heroin. Capture-recapture studies carried out between 2001 and 2014 indicate that 
there are a significant number of problem opiate users in Ireland. The national point 
prevalence estimate of opiate users in 2014 was 18,988, giving a rate of 6.18 per thousand 
population aged 15‒64 years (95% CI: 6.09‒6.98). The prevalence of problem opiate use in 
Ireland has stabilised but remains amongst the highest in Europe [20]. Recent national trends 
indicate that the incidence of injecting opiates is declining [21]. There has been a steady 
decline in the total number of new entrants to treatment reporting opiates as their main 
problem drug with a drop from 58.1 % in 2010 to 47% in 2016 [22].  The percentage who 
had ever injected among new treatment entrants for problem opiate use has also decreased 
significantly over time from 71% in 2004 to 64% in 2015 [21].  
The Irish government introduced opiate substitution therapy (OST) and needle exchange 
programmes in Ireland in 1989 in response to an increasing HIV prevalence in PWID. OST is 
now provided nationally through a network of specialised HSE outpatient treatment 
clinics/satellite clinics, specially trained level 1 and 2 general practitioners in the community 
and prisons [23]. All OST patients are registered on a central treatment list (CTL). The 
number of clients on this list has increased each year since 2006 and there are now over 
10,000 people on OST in Ireland [23].  
The ongoing criminalisation of drug users in Ireland impacts on the levels of HCV infection 
in Irish prison populations. Over 60% of the 3,400 prisoners incarcerated on a daily basis 
have a history of drug use with over a quarter reporting a history of IDU [13]. It is recognised 
that the majority of Irish prisoners come from marginalised communities with high levels of 
poverty, social deprivation, unemployment, illiteracy, physical and mental illness including 
addiction and blood borne virus (BBV) infections [24]. Like other prisoners, Irish inmates are 
identified as a hard to reach group for medical interventions and have poor access and uptake 
of traditional community medical services [24, 25]. 
 
Like other European countries, Ireland is upscaling HCV screening and treatment services 
[14, 26–28]. Direct acting anti-virals (DAA), mobile elastography and the movement of HCV 
treatment in the community, coupled with less restrictive HCV treatment guidelines have 
revolutionised the HCV treatment landscape [29–32]. Ireland’s national treatment program 
has signed up to the Global Health Sector Strategy on viral hepatitis for 2016-2020. The 
program aims to eliminate HCV as a major public health threat in Ireland by 2030 [33]. The 
roll out of new highly effective treatment in Ireland offers an exciting opportunity to achieve 
this goal yet many challenges to up scaling HCV screening and treatment to effective levels 
still remain. Understanding the burden of HCV disease and the barriers to screening, 
assessment, treatment and prevention in people who use drugs (PWUD) and prisoners in an 
Irish context is imperative in the planning and implementation of an effective national HCV 
strategy.  
 
This scoping review collects and summarises the literature on HCV infection in PWUD and 
prisoners residing in Ireland. This review can, act as a baseline by which to monitor progress, 
support focused action and inform national and international public health HCV elimination 
strategies that target PWUD and prisoners as key at risk populations. This review also aims to 
identify gaps in the Irish-based HCV literature related to PWUD and prisoners and assess 




This scoping review of HCV infection in drug users and prisoners in Ireland was conducted 
by applying the methodological framework set out by Levac and colleagues which was based 
on prior work by Arksey & O’Malley [34, 35]. The steps include; identifying the research 
question, identifying all relevant studies, selecting significant studies, charting the relevant 
data and then summarising and reporting the results. The rationale for using this methodology 
was to determine what is known about HCV infection in Irish PWUD and prisoners by 
reviewing all available literature (quantitative, qualitative, guidelines and policy documents) 
on these two groups and to map the key findings and concepts emerging from this body of 
literature. A further aim was to map gaps in the literature which will inform future research.  
A broad search strategy was conducted in order to identify all relevant studies. Databases 
searched included PubMed, Science Direct, EMBASE, PsycINFO, Cochrane library and 
Medline. No limits were placed on dates. The key terms we used for this search were the 
MeSH terms, “hepatitis C” and [“prison” or “prisoner”] and “drug users” and “Ireland” or 
similar non-MeSH terms outside PubMed (appendix 1). Follow up search strategies included 
hand searching relevant national websites including the Health Service Executive (HSE), 
Irish Prison Service (IPS), Departments of Health and Justice (DOH and DJ), the Irish Penal 
Reform Trust (IPRT), Health Surveillance Protection Centre (HSPC) and European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA). National experts and authors 
of existing papers were contacted to identify possible sources of unpublished and grey 
literature. Reference list were also manually searched by the team to identify relevant studies 
or literature not captured. References were managed by the citation manager Endnote®. This 
software facilitated the recording and organisation of all relevant literature and also allowed 
for the cross checking of data records, removal of duplicates and extraction of information 
from the papers included in the review. The literature search was completed in June 2018. 
Eligibility criteria for study selection centred on whether studies broadly reported on any 
aspect of HCV infection in Irish PWUD or prisoners including those that reported findings 
from analysis of these groups within broader populations. Publications to be included were 
peer-reviewed research, published reports, guidelines and strategies, editorials, commentaries 
and audits. Articles were excluded if they did not report results on these specific cohorts. 
Researcher 1(DC) analysed all articles found by title to select those that were potentially 
relevant. The abstracts of all studies selected based on their titles were independently 
evaluated by researcher 2(RM) and any discrepancies were kept in the analysis.  
Data was extracted and charted from all studies selected at the abstract stage, using an 
instrument designed for this study covering; date and author, setting, study population and 
sample size, data collection period, study design, HCV prevalence and associated risk factors, 
HCV incidence, treatment outcomes, barriers and facilitators to HCV care, knowledge and 
experience of living with HCV, recommendations on the management of HCV and other 
outcomes. Data was extracted for each paper by a single researcher (DC) and checked by a 
second researcher (RM) to ensure that data extraction was accurate and comprehensive. The 
final decision to include studies was made based on this data extraction and whether it met 
the inclusion/exclusion criteria, based on independent evaluation by two authors (DC and 
RM), and a discussion of any discrepancies with the third author (TMcH).  
A qualitative synthesis of the literature was carried out. The process of navigating and 
redefining the findings was iterative, and the researchers engaged with each stage in a 
reflexive manner, by fine tuning and repeating steps so as to ensure comprehensive synthesis 
of literature. Papers reporting on HCV incidence, prevalence, risk factors and screening 
uptake were categorised as epidemiological and reported and interpreted according to year of 
publication. For ease of reporting and interpretation this largest category was sub-categorised 
into those published in the last decade (2008-2018) and more historical studies published 
before 2008. The identified studies in this category reported on different populations 
(prisoners, PWID and PWUD on OST) and settings (prison, drug treatment centres and 
general practice).  
The majority of the relevant literature retrieved from the web-site searches were either 
national reports, strategy documents or guidelines and were categorised as such. Studies 
reporting on outcomes following HCV diagnosis (self –clearance and sustained virologic 
response (SVR)) were categorised as treatment outcomes. The remaining literature was a mix 
of qualitative and quantitative studies that reported on a variety of outcomes including HCV –
related health issues, alcohol consumption and patient and health provider experience of 
HCV infection and/or treatment and for convenience of reporting were categorised into HCV-
related health issues and patient and health- providers’ experience. Where studies reported on 
a number of outcomes that crossed categories, these studies are categorised in the tables 
according to main/primary outcome and each outcome is reported in the result section 




Initial screening identified a total of 160 of which 27 were from grey literature and manual 
searching of reference lists. 117 met the inclusion criteria on title. Following a review of 
abstracts 42 studies were excluded. The remaining 75 studies were read in full and a further 
17 were excluded. A total of 58 studies covering the period 1983-2018, were included in the 
final data synthesis (Fig 1).   
 
Five broad categories were identified to assist in the organisation of the literature. These 
were; Epidemiology, Guidelines and Policy, Treatment Outcomes, HCV -related Health 





For clarity the epidemiological studies have been grouped into studies reporting on HCV 
incidence and prevalence pre and post 2008. Within these time frames the studies are further 
categorised according to study population (prisoner, PWID and PWUD) and community 
location (drug treatment centre or primary care). The findings from studies reporting on risk 
factors and HCV screening uptake along with identified gaps in surveillance data are reported 
at the end of this section. 
Pre-2008 (22 studies) 
Incidence (2 studies) 
 
Two studies reported on HCV incidence in the pre-2008 period. The first was a 2003 a 
single-site study on HCV negative PWID attending methadone maintenance treatment 
(MMT) at the National Drug Treatment Centre (NDTC). Follow up screening on 100 patients 
found an HCV incidence of 66 (CI 51-84) per 100-person years (py). A larger 2005 study 
involving 21 drug treatment centre sites and 1459 PWUD reported an incidence of 24.5 per 
100 py. [36, 37].  
 
Prevalence (20 studies) (Prisoners =3 studies, PWUD = 7 studies, PWID = 8 studies) 
 
A total of papers was identified reporting on the prevalence of HCV infection in PWUD and 




Two studies were prison-based, one a randomised national study of the general prison 
population, the other was conducted on committal prisoners only. The 2000 study of 9/15 
prisons in the Republic of Ireland (ROI) reported an anti- HCV prevalence of 37%, 
increasing to 81% among those prisoners with a history of IDU. The 2001 multi-site 
committal study reported an anti- HCV prevalence of 3% in those who had never been 
imprisoned previously, 22% in prisoners aged 19-25, increasing to 72% in prisoners with a 
history of IDU [38].  
 
An interesting 2000 prison-based study reported on the discrepancy between self-reported 
HCV status and actual status (confirmed by oral swabs). Based on self-report the HCV 
prevalence estimates were 19% but actual prevalence was double this rate (37%) with small 
numbers (5%) reporting being anti-HCV positive erroneously [16].  
 
PWUD (Drug Treatment Centres = 4 studies, Primary Care= 3 studies) 
 
Nine studies reported on HCV prevalence in PWUD attending MMT in community drug 
treatment clinics. The first was a 2001 multi-site randomised chart review of 715 patients 
attending MMT. This study reports an anti-HCV prevalence of 78.8% which reduced to 52% 
in those under 25 [39]. The 2005 incidence study described above reported an HCV 
prevalence of 66% in a population of PWUD attending drug treatment across 21 sites in the 
Dublin region [37]. A single site study from the NDTC reports an anti-HCV prevalence of 
81.6% among study participants attending the centre for MMT during a 3-month period in 
2002 [40].  A unique 2004 study reported an anti-HCV prevalence of 27% among adolescent 
drug users attending drug treatment, increasing to 55% among those with a history IDU [41].  
 
A 2003 study involving 531 PWUD attending MMT at 42 general practice locations reported 
an anti-HCV prevalence of 78% [42]. A single site 2005 study reported an anti-HCV 
prevalence of 88% [43]. A later 2007 multi-site study reported an anti-HCV prevalence of 
69% [44].  
PWID (Drug Treatment Centres=7 studies, Primary Care = 1 study) 
 
A 1983 paper reported on the identification of non-A non-B exposure in 90% of a cohort of 
PWID with acute hepatitis undergoing biopsy at a single hospital site in Dublin [45].  
 
Four studies were single site studies from the NDTC (1995-2000) three of which were on 
new entrants with varying lengths of IDU history. Among new entrants HCV prevalence 
ranged from 52% - 61.8% [17, 46, 47]. The single 1995 study reporting on HCV prevalence 
among PWID on methadone maintenance treatment (MMT) reported an anti-HCV prevalence 
of 84% [48]. 
 
A 2003 single-site study was the first to report on the prevalence of chronic HCV infection 
and genotype distribution in a PWID cohort. Of the 94 included in the prevalence part of this 
study, 74.5 % were anti-HCV positive, 41.5 % where HCV-RNA positive (chronic HCV 
infection).  The genotype distribution was 66.6% genotype 1 and 25.6% genotype 3. This 
study also included a mathematical modelling component to estimate national HCV burden 
levels [49]. These findings are reported in a later section of this review. A multi-site 2005 
study involving 496 patient’s mono-infected with HCV of whom 127 (with demonstrated 
self- clearance on initial testing) were followed up two years later. The initial testing showed 
a self-clearance of 38% which when followed up two years later had reduced to 31.1%. The 
genotype distribution reported in this study was genotype 1 = 48.8% and genotype 3 = 48.5% 
[50]. A 2005 multi –site study (10 sites including 2 residential drug treatment sites) reported 
an anti-HCV prevalence of 61% among PWID who had a history of IDU in the past six 
months but who had never tested for HCV [51].  
 
Only one single-site study reported specifically on HCV infection in PWID in primary care. 
This unique longitudinal study followed a cohort of 82 PWID attending a south inner-city 
Dublin general practice over 25 years. At the beginning of the study HCV infection had not 
been identified but at 10-year follow-up, 33% of those still alive had been infected. At 25-
year follow-up 40% of survivors were anti-HCV positive [52].  
 
At -risk population associated with PWUD (2 studies) 
 
Two studies reported on HCV prevalence in groups associated with PWUD. A single 2001 
study reported that 82% of infants referred to an outpatient paediatric HCV clinic where from 
mothers with a history of IDU [53]. A 2008 study of homeless people found high levels of 
PWUD among this group (64%) as well as a high prevalence of HCV exposure (36%) [54].  
[Insert table 1 here] 
Post 2008 (10 studies) 
Incidence (1 study) 
A 2016 study using mathematical modelling and data on 14,320 PWID registered on the 
NDTRS estimated that 12,423 (CI 10,799-13,161) PWID were infected with HCV from 
1991-2014, 9,317 (CI 8,022-9,996) of whom had chronic infection. This paper also reported 
that new infections peaked in 1997, and that almost three quarters of those infected have the 
disease for greater than 10 years [19]. 
Prevalence (9 studies) (Prisoner = 2 studies, PWUD = 6 studies, PWID=1 study) 
Prisoner 
A 2014 study conducted in 13/15 of the prisons in the ROI reported an anti-HCV prevalence 
of 13% (95% CI 10.9-15.2%) among the general prison population, increasing to 41.5% in 
prisoners with a history of IDU and 54% in those with a history of injecting heroin [13]. The 
most recent prison study from 2014 (single –site) reported an HCV prevalence of 37% among 
prisoners on MMT [55].  
 
PWUD (Drug Treatment Centres = 5 studies, Primary Care= 1 study) 
 
Two 2014 studies identified from the grey literature reported on HCV infection in PWUD 
attending MMT in drug clinics outside of Dublin and reported an anti- HCV prevalence less 
than Dublin based studies (24%%) [56, 57]. A published 2017 study reported an anti-HCV of 
63.6 % among PWUD attending MMT at a North Dublin inner city treatment centre [58]. 
Two recent large HCV screening audits, identified through the grey literature search, reported 
an anti-HCV prevalence of almost 80% and a chronic HCV prevalence of 65% among 
PWUD attending MMT at 23 drug treatment clinics in Dublin [59, 60].   The most recent 
prevalence study in PWUD attending OST in general practice reported an anti-HCV 
prevalence of 77.2% among this group [61]. 
 
PWID (1 study)  
A study conducted on PWID attending an inner-city accident and emergency department 
showed high levels of morbidity and HCV exposure (74%) [62].  
 
[Insert table 2 here] 
  
HCV Risk Factors 
 
A total of 13 studies (1995-2017) reported on risk factors for HCV acquisition in both 
prisoner and PWUD populations. Prisoner risk factors identified were; a history of IDU, 
sharing needles while incarcerated, sharing drug taking equipment, older age, female gender, 
a previous history of incarceration and a history of having a prison tattoo. [13, 63, 64]. For 
drug users attending community-based OST risk factors identified were; a history of IDU, 
increased total number of lifetime injecting, closer social relationships with PWID, injecting 
in the homes of other PWID, a history of imprisonment, older age, male gender, drug use 
prior to 1989, co-infected with HIV or HBV, younger age of first drug use, first IDU and 
entry to MMT and type of drug first used [6, 17, 36, 37, 39, 42, 48, 51, 53, 58]. 
 
HCV screening uptake  
 
A number of the epidemiological studies reported on HCV screening uptake among the study 
population. The first was a 2001 multi-site randomised chart review of 715 patients attending 
MMT. This study reports a screening uptake of 60%. The larger 2005 Dublin based multi-site 
study involving 1459 PWUD reported an 88% uptake of HCV screening 
A single site study from the NDTC reports very high levels of HCV screening uptake and an 
anti-HCV prevalence of 81.6% among study participants [40]. However only a third of anti-
HCV patients were RNA tested showing a chronic HCV prevalence of 15.6%. This study also 
found high levels of accuracy for HCV self-report [40].   
 
A 2003 study involving 531drug users attending MMT at 42 general practice locations 
reported that over two thirds had an HCV screen [42]. Two large HCV screening audits, 
identified through the grey literature search, reported high levels of HCV screening [59, 60]. 
Dublin. Uptake of HCV screening was less than in Dublin clinics (50%) (Horan, 2014; Ryan 
& Ryan, 2014) The Cork (second largest city in Ireland) study identified that chart labelling 
(starring) had a positive impact on the uptake of screening among this patient cohort [57]. 
The most recent prevalence study in PWUD attending OST in general practice reported high 
uptake of HCV screening (92.5%) [61]. A later 2007 multi-site study reported high levels of 
HCV screening among PWUD on MMT in Dublin based general practice (77%) [44]. Only a 
third of those infected had been screened for chronic infection (36%) [44].  
 
Identified Gaps  
 
No studies reported on incidence infections specifically in prisoners, PWUD or PWID in 
general practice or not on OST and PWUD without a history of IDU. Only two studies 
reported on HCV prevalence in PWUD outside of Dublin and both where from secondary 
urban centres. The majority of the prevalence studies are over a decade old and only report on 
anti-HCV prevalence and not on HCV-RNA prevalence which limits their usefulness at 
estimating the levels of chronic untreated infection and re-infection. The most recent 
epidemiological studies included in this review are mostly chart review audits which limit 







Guidelines and policy (8 studies) 
 
A total of 8 documents were identified that fitted into this category. The first published 
national document relating to HCV infection in PWUD and prisoners was published in 2004 
[65]. This was a regional (Dublin-based) document that reported on the views of 70 
stakeholders (service planners, funders, providers and users) on a broad range of HCV related 
issues including policy and clinical issues [65]. 
In the same year, a research lead initiative developed consensus guidelines on HCV 
management in general practice [66]. The effectiveness of these guidelines was later 
evaluated in a cluster randomised trial and were found to improve the uptake of screening in 
practices where the policy was implemented (OR = 3.76 CI= 1.3-11.3) [67].  
The National Hepatitis C Strategy 2011-2014 was the first published strategy relating to all 
those infected with HCV in Ireland [14]. The strategy spans surveillance, prevention, 
screening and treatment of HCV infection and reports on both groups (PWUD and prisoners). 
The Department of Health (DOH) subsequently published a report: A Public Health Plan for 
the Therapeutic Treatment of Hepatitis C in 2015 which recommended the establishment of 
the National Hepatitis C Treatment Programme (NHCTP) in the HSE [68]. 
The NHCTP was established in 2014 and oversees treatment provision to all HCV infected 
patients in Ireland, including PWUD and prisoners [26]. This program has a number of 
specialist committees that advise on the treatment criteria and guidelines and also includes a 
treatment register which collects data on treatment uptake and outcomes. 
The HSE developed national HCV screening guidelines to identify HCV-infected individuals 
who are currently unaware of their HCV status [10]. These guidelines were preceded by two 
opioid substitution guidelines that contained recommendations on the screening of drug users 
on OST [69].  
The Irish Prison Services are responsible for the provision of health care in all prisons in the 
ROI and in parallel to community-based guidelines have further sets of guidelines that deal 
specifically with HCV management within the IPS [70]. The provision of all healthcare, 
including HCV treatment is guided by the international principle of community equivalence 
of care [71].  
The major gap identified in this category is that the national strategy was published pre-DAA 
and no longer reflects the reality of HCV treatment in particular the challenges related to 
moving HCV treatment from hospital services to the community. The new national HCV 
screening guidelines provides a clear road map on who to screen but to date there is not data 
on the success of their implementation. It is also important that the IPS update their health 
care standards in line with the new national screening guidelines and NHCTP to ensure 
community equivalence.   
[Insert table 3 here] 
Treatment Outcomes (13 Studies) 
 
A number of papers reported on treatment uptake and outcomes. These studies found poor 
engagement with hepatology services for liver assessment and treatment by PWUD [43, 44, 
61, 72–74]. Predictors for poor treatment follow up were, younger age, active IDU and 
advanced HIV disease, male gender [75, 76]. A single prison study reported that no HCV 
infected prisoner on MMT was on HCV treatment at the time of the study [55].   
 
A number of studies reported SVR from interferon -based treatment and found SVR ranging 
from (53% -74%) with PWID having similar outcomes to other patients [75–78].  
 
In-reach hepatology services provided HCV treatment at two Dublin based prison location. 
An audit of these sites shows high compliance with treatment and good treatment outcomes 
[79]. 
A single study reported on the use of tele-medicine as a novel approach to increasing 
treatment among HCV infected PWUD attending MMT. This study showed high levels of 
satisfaction among professionals engaging with the initiative [80]. 
A number of gaps in the treatment outcome literature were identified including: the lack of 
SVR outcomes for DAA treatment, re-infection rates and treatment uptake and completion 
rates. There are no mathematical modelling studies conducted using existing surveillance data 
and treatment uptake and outcomes to map pathways towards HCV elimination in Ireland.  
[Insert table 4 here] 
HCV -related Health Issues (8 studies) 
A number of studies reported on HCV related health issues.  Two hospital-based studies 
found higher levels of depression and anxiety among HCV infected patients whose risk factor 
for acquisition was IDU [81, 82].  
A 2003 mathematical modelling study estimating the national HCV- related disease burden 
over 20 years, predicted 1,214 cases of cirrhosis, 35 cases of HCC, 60 cases of hepatic 
decompensation and 50 cases of liver related deaths per annum [49]. 
 A number of papers describe high levels of alcohol use among HCV infected PWUD (41%) 
[40, 73, 83]. Studies report high levels of HCV-related liver disease and awareness that 
excessive alcohol had a negative impact on HCV disease progression among PWUD on OST 
[74, 83] [40].   
 
A 25 year follow up study of PWID attending general practice found high levels of mortality 
in a cohort with HCV exposure having a negative impact on life expectancy (O’Kelly & 
O’Kelly, 2012). A unique five-year follow up study among PWUD attending OST showed 
high mortality rates of among patients with high Fibroscan scores which was associated with 
heavy alcohol use. The study concluded that a single Fibroscan score was highly predictive of 
mortality (McCormick et al., 2014). 
Overall the research on HCV related health issues was considered to be scant and incomplete. 
While a number of studies report on levels of liver disease in small groups of PWUD on 
OST, the literature does not provide a clear picture of the HCV disease burden in these two 
groups. In the early days of DAA treatment HCV infected patients with advanced liver 
disease were prioritised for treatment access but it is unclear how many of these accessed or 
completed treatment.  There is also no published data on the numbers of HCV infected 
PWUD who die annually from non-HCV related causes. This may be considerable given the 
high levels of drug related deaths in Ireland and if not accurately quantified will have an 
impact on Irish HCV elimination strategies. 
[Insert table 5 here]  
Qualitative research reporting on Patients’ and Health Providers’ Experiences 
 
A number of studies report a high awareness of HCV infection among PWUD on OST both 
in primary care and drug treatment centres [40, 43]. This includes the knowledge that IDU is 
a major risk factor for transmission among this group and the health implications of being 
infected [43]. There were also high levels of awareness of patients own HCV status, of HCV 
harm reduction measures, and adverse effects alcohol has on the progression of HCV liver 
disease [40, 43]. 
 A prison–based study exploring the health needs of female prisoners using focus group 
methodology reported that HCV infection was identified as a health concern among Irish 
female prisoners [25].   
 
A single study reported on negative patient experiences with regard to testing, assessment and 
treatment [43]. HCV related stigma was reported in many of the qualitative studies [25, 43, 
74, 82, 84–86]. 
 
A number of studies identified barriers to PWUD  engagement  in HCV treatment including; 
ongoing alcohol and drug use, fear of HCV treatment and liver biopsy, imprisonment, 
distance to hospital, early morning appointments, perceptions of HCV infection as relatively 
benign, fear of investigations and treatment including liver biopsy and interferon, feeling 
well, limited knowledge of testing sites, not being referred for specialist investigations, 
ineligibility for treatment and competing priorities (employment, education, and 
addiction)[43, 74, 80, 85]. Some of these studies reported on enablers to PWUD engagement 
which included; afternoon appointments, enhanced prison referral mechanisms into the 
community, community fibroscanning, location of services within the addiction treatment 
services,  relationships with health care providers, trust in providers, concern for the service-
user, continuity of care, education on HCV infection, investigations, and treatment, becoming 
symptomatic, responsibilities for children, wanting to move on from drug use [74, 85].  
 
Only two studies reported on healthcare professionals’ experience of providing care to HCV 
infected prisoners and PWUD.  A single prison study reported lack of knowledge regarding 
BBVs including HCV had a negative impact on prison officers’ work [87]. A recent study 
identified lack of time and inadequate funding as barriers to community GPs engaging with 
HCV treatment [80]. 
As previously identified the major deficit in this category is that it reports from a pre-DAA 
era. This is particularly relevant for barriers to treatment engagement which was related to the 
fear and experience of side effects of interferon- based treatments. There is a need to conduct 
more up to date quantitative research on PWUD S’ and prisoners’ experience of the HCV 
treatment cascade with DAA treatments. This can best inform the planning of effective HCV 
delivery systems.  




Overall this review found a larger than expected quantity and greater scope of literature 
published on HCV infection in Irish prisoners and PWUD. The literature was both 
quantitative and qualitative, employed many different methodologies and covered a 35-year 
period from 1983-2018. 
 
The majority of the studies are epidemiological and report on HCV prevalence in both 
cohorts. This scoping review found that Ireland has low rates of HCV infection in the general 
population compared to other European countries [5, 27, 88, 89]. The most up to data 
(residual sera study) showed a reduced prevalence compared to a 2012 mathematical 
modelling study [6, 9]. The different rates could be explained by the differing methodologies 
or by a reduction in new infections. The absence of a population prevalence study makes it 
difficult to have a true HCV population estimate and impacts on the development of 
strategies to identify the undiagnosed population [6, 90]. 
 
This review found that IDU is the most common risk factor for HCV acquisition in Ireland 
and that the prevalence of HCV infection in Irish prisoners and PWUD is much higher than 
the general population. The prison-based studies included in the review found a reducing 
HCV prevalence with the most recent study (2014) reporting a prevalence of 13% [13]. This 
is much lower than the global estimates of 25% [11] but similar to other European country 
estimates [5]. The prevalence of HCV in all groups of PWUD and PWID is over 50%. Again, 
this is in keeping with other global and European estimates for this group [2, 5].  The 
majority of the studies included in the review are over a decade old, only include drug users 
on OST and all but two are Dublin based. There is a paucity of up to date literature on HCV 
prevalence in PWUD from outside Dublin and none at all on PWUD not on OST. A small 
number of studies reported on rates of chronic infection, but no study reported on the 
population based chronic HCV prevalence. This is a significant deficit in the literature as it 
does not allow for accurate estimates of untreated HCV infections and re-infections [91].  
 
This review also found low levels of RNA testing for those identified as anti-HCV positive. 
Consideration should be given too adapting a reflex-RNA testing approach to HCV screening 
in Ireland [10]. This has the potential to reduce the number of bloods required in a group 
where venepuncture can be difficult and an indemnified barrier to engagement in HCV care 
[92].  As Ireland scales up HCV screening and treatment it is important that accurate data on 
levels of active HCV infection is available to optimise and evaluate the effectiveness of the 
national HCV strategy.  
  
This review identified significant strategy, policy and guideline documents published over the 
last 14 years related to HCV. These provide a broader national context in which to interpret 
the literature and allow for comparisons to made with international and European strategies 
aimed at HCV elimination [27, 28]. However, it is concerning that the national strategy was 
published in 2012 and much of its content relates to interferon-based treatments and related 
challenges [14]. While the NHCTP provides up to date recommendations on HCV treatment 
[26], a new strategy is required to support the upscaling of HCV care, in particular, its 
movement into community addiction services and primary care. The national screening 
guidelines provide a useful guide to active HCV case identification [10]. These guidelines 
need to be underpinned with adequate resources and an evaluation to measure their 
effectiveness in identifies what is considered to be a significant level of hidden HCV 
infection in Ireland [6].  
 
A handful of studies in this review report on treatment uptake and outcomes and on the lived 
experience of Irish HCV infected prisoners and PWUD [43, 44, 55, 85]. The evidence 
suggests poor uptake by HCV infected community PWUD with hospital-based services. This 
review also identified the many barriers related to HCV treatment uptake by this group [74, 
85]. Many of these barriers are associated with previous interferon-based treatment and will 
be eliminated by the availability of DAA [29, 30]. This review also reports a number of 
facilitators to HCV engagement by Irish PWUD including the movement of HCV treatment 
out of specialised hospital services into community OST clinics. The success of this approach 
has been reported previously in the literature [93, 94] and is now the strategy being adapted 
the NHCTP [26]. This review found that treatment outcomes were not negatively impacted 
by patients having a history of IDU, however active drug use was identified as having a 
negative impact on treatment engagement. These findings need to be viewed with caution 
since they are related to interferon-based treatments [78]. Many patients were excluded from 
accessing treatment based on; a history of active IDU, excess alcohol or other drug use, 
concerns regarding relapse or mental health issues [93, 95]. Treatment was also only 
provided in specialist hospital services and only imitated after many hospital visits. This 
ensured that only the most stable and compliant PWUD accessed treatment. Broadening 
treatment eligibility. increasing treatment locations and the use of short acting pangenotypic 
DAA will engage many less stable PWUD with HCV care [29, 30]. It is important the real-
world data is available to monitor SVR post treatment and re-infection rates [96]. Similar to 
other published studies this review found SVR rates in prisoners equal or better that in the 
community [97, 98]. But challenges remain in screening and engaging more prisoners in 
HCV care [99]. This review found no studies reporting on prison-based barriers and 
facilitators to HCV care.  
  
There is very little data available on the levels of HCV related liver disease in PWID and 
prisoners [100]. Where available, the evidence supports increasing levels of morbidity and 
mortality in these groups [100, 101]. This review found that HCV infection was associated 
with increased mortality and that problem alcohol use was common among HCV infected 
PWUD. Irish epidemiological studies report that there is an aging cohort of HCV infected 
PWUD, the majority having the infection for over 10 years. It is reasonable to expect that 
there is significant related liver disease in this cohort. While this group where initially 
prioritised for DDA treatment there is no data on how many of this high-risk group remain 
untreated. Studies on rates of HCV related liver disease and treatment uptake in this high-risk 
groups are required to ensure that are treatment strategies are successful in reducing HCV 
related morbidity and mortality. 
Noticeable gaps identified in the literature on HCV in Irish prisoners and PWUD was the lack 
of studies, on strategies to prevent HCV infection and rates of incident infection in both 
groups. Ireland has a well-established network of harm reduction services including OST and 
needle exchange programs which are known to be effective in reducing HCV infection if 
provided with adequate coverage [102, 103]. However, there is no data available on their 
effectiveness in an Irish setting. Monitoring the rates of new infections will provide an 
indicator to the success of harm reduction services and the impact of treatment as prevention 




This review summarises the literature on HCV in Irish PWUD and prisoners. The findings 
show that in Ireland, 0.5% of the general population have chronic HCV infection (60% 
undiagnosed), 13% of prisoners and over 50% of PWUD on OST have been exposed to HCV 
infection. People with a history of injecting heroin carry the greatest HCV disease burden in 
Ireland, with the majority having the infection for greater than ten years. Increasing HCV 
related morbidity and mortality in this cohort, particularly in those with problem alcohol use 
is a concern. Irish PWUD engage poorly with hospital-based services and many barriers to 
HCV treatment uptake in this cohort have been identified. HCV treatment outcomes in Irish 
PWID is similar to other patient groups. In-reach hepatology services to Irish prisons has a 
positive impact on both uptake and successful completion of HCV treatment and its 
expansion to all prisons in Ireland should be considered. This review identified a range of 
policy and strategy documents that can inform national HCV screening, treatment and 
prevention programmes. A number of gaps in the literature were identified including; lack of 
reliable national prevalence data on untreated HCV infection (general population, PWUD and 
prisoners), accurate estimates of HCV related disease burden, HCV incidence infection in 
both PWUD and prisoners, barriers and facilitators to prisoners engaging with HCV services 
and HCV treatment uptake and outcomes in both groups. The lack of HCV epidemiolocal 
data on PWUD outside of Dublin and those not on OST is a concern. It is also important that 
policy and strategy documents are kept current to reflect international evidence-based 
practice and are informed by more accurate HCV surveillance data. This review is timely as 
Ireland scales up community-based HCV screening and treatment and gathers the available 
literature on HCV in Irish PWUD and prisoners. It is a useful starting point and can be used 
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Figure 1: Flow diagram 
 
Additional Files  
File name 
Additional file 1  
Title of data 
Search strategy and excluded studies  
Description of data 
This file shows an example of the search strategy used for PubMed and the bases on which 



























Table 1: Epidemiology Pre-2008 
 Date and 
author 
Setting Sample (n) Data 
collection 
Design  Main results 
Prisoners 
[18] 2000 














Anti-HCV= 37%  
(95% CI=34.3% to 39.9%)  80% among prisoners with a Hx of IDU   60% of women and 42% of men had Hx of 
IDU  20% first IV in prison and 71% shared 
needles  
 
Significant risk factors (p<0.05):  IDU  Hx of sharing while in prison 
[16] 2000 



















Anti-HCV = 37%  
Self-report anti-HCV = 19%  
  Among those self-reporting being anti-
HCV positive, 5% were negative on oral 
fluid assay.  Among those reporting a previous negative 




Long et al 
National 
Multi-site 













study on new 
entrants and 
risk factors  
 
Anti-HCV = 22 % (CI: 19% - 25%)  anti HCV = 72% (Hx of IDU)  anti HCV = 3 % (Never in prison) 
 











retrospective   

















 60 % screened   Among those < 25 yrs., anti-HCV 










Drug users on 
MMT     
(531; m=443) 





Anti-HCV = 78% 
  67% screening documented   193 had screen completed by GP, 
74 another service and 113 no 
screen but self-report from patient   Predictors of being screened  Hx of imprisonment  documented HIV neg  Hx of IDU 
 
Significant risk factors (p<0.05):  age >26  Hx of IDU  Hx of imprisonment drug use prior to 1989    HIV pos/HBV pos 
[41] 2004 












1998 - 2001 (Letter – 
response to 
Kavanagh et al 
2003) 
Anti-HCV = 27% 
Anti-HCV among declared injectors = 55% 
 
Mean duration of injecting:  Anti-HCV positive = 1.42 yrs.  Anti-HCV negative = 1.16 yrs. 
[37] 2005 













(one in four 
consecutive 
sampling) 
Anti-HCV = 66% 
Incidence 24,5 per 100 years 
88% tested for HCV  
 













(196; m= 100) 
 Cross-sectional  
Prevalence 
Anti-HCV = 69%   77% screened for HCV   36% of those anti-HCV were tested for 
HCV-RNA   30% were referred to hepatology  24 % attended the clinic   13% had a liver biopsy  3% had started treatment  
[54] 2008 





(393; m= 61%; 
drug users = 
64%) 
 






Anti-HCV = 36% (95% CI: 31%-41%) 
[40] Noonan et al 
2009 






Sept-Dec 2002 Cross-sectional 
survey 
Anti-HCV = 81.6% (untested = 2.8%) 
HCV RNA = 15.6 % (untested = 65%)  Most of the study participants had accurate 
self-reported of HCV status 
 
Problem drinking:  Prevalence (audit score) = 41% (95% CI 
33-51%).  98% agreed that ‘alcohol may worsen HCV 
related liver disease’   92% agreed that ‘reducing alcohol 














Jan-April 1981 Cross-sectional  
prevalence 
study 
90% had exposure to non-A non-B (HCV) 
(27; m= 22; 
mean age = 
20.8 yrs.; 











PWID on OST 







Anti-HCV = 84% 
 
Significant risk factors (p<0.05):  male gender  > 2 years Hx IDU 
[17] 1998 















Anti-HCV = 61.8%  
(95% CI = 58.3-65.3) 
 
Significant risk factors (p<0.05):  older age  longer HX of IDU  IDU before 1990  daily expenditure > 65 punts 
[47] 1999 







PWID - new 
entrants with 
HX IDU of < 
25 months 








Anti-HCV = 52.1% 
  ↓ risk for those starting IDU after 1993 and 
with IDU < 13 months 
[72] 2000 





















Anti-HCV = 54% 
  21/119 completed assessment  48 tested for HCV  13/26 HCV infected left OST treatment 
before receiving result   4/19 attended on-site hepatology services  
[53] 2000 














(296; PWID = 
244) 
 




HCV RNA: 55% (84 tested) 
  82% infected via IVDU 
[49] 2003 























Anti-HCV = 74.5% 
HCV RNA = 41.5%  Genotype 1 = 66.6%  Genotype 2 = 2.6%  Genotype 3 = 25.6% 
 


























up repeat HCV 
test = 100)  
 












HCV seroconversion = 67%  
Incidence= 66 per 100-person years (CI: 51-84 per 
100-person years) 
 
Of 74 patients who were retested within 24 months   HCV seroconversion = 61%  Incidence = 100 infections/100 person 
years (95% CI: 73/100 to 134/100 person 
years). 
 
Significant risk factors (p<0.05):  Hx IDU  Hx imprisonment 
[51] 2005 











PWID - IV in 
the past 6 
















Predictors of positive test result (p<0.05):  increased total number of lifetime injecting 
episodes  closer social relationships with other IDUs  injecting in the home of other IDUs 
 














effects of HCV 
guidelines  
Intervention group   ↑ HCV screening (OR = 3.76; 95% CI = 
1.3 to 11.3)    referral to a hepatology clinic (p = 0.06) 
[6] 2012  
Thornton et al 


















General population estimate for chronic HCV 
infection = 20,000- 50,000 (0.5-1.2%).   10,000 people diagnosed anti-HCV 
between 1989-2004, peaking in 2000.  Genotype 1 = 55% and Genotype 3= 39%.  Drug use most likely risk (80%).  Median age of diagnosis is 28.  70 % of 
those infected though drug users were 
male.   Median age 
at diagnosis for those infected through drug 










Table 2: Epidemiology post 2008 
 Date and 
author 
Setting Sample (n) Data 
collection 









(817; m=772; Hx 
IDU = 26%) 
2011 Observational Cross-
sectional prevalence study 
including self- administered 
drug and risk questionnaire  
Anti-HCV prevalence = 13% 
 
Significant risk factors (p<0.05):  Hx of IDU and sharing drug taking 












October 2011 Patient Survey 
Retrospective chart review 





Single site  
Drug Users 
fibroscaned 
 Letter – reporting on five 
year follow up study 
Anti-HCV = 74.4% 
HCV-RNA = 58.3%,  




attending MMT  
(84; m= 66) 
Heavy alcohol use= 37% 
 
Five-year mortality = 15% (Liver related 
deaths = 6; probable liver related = 1; drug 
overdose = 5; laryngeal carcinoma = 1) 
  5/6 patients who died of liver disease, 
were HCV RNA-positive with heavy 
alcohol use  Mean liver stiffness values were 
higher in patients who died compared 
with survivors (28.5 kPa ±7.9 vs. 9.0 
± 1.5, P = 0.0045)   Mean liver stiffness values were 
higher in patients with liver-related 
death compared with survivors (50.6 
± 11.2, P < 0.0002).  12 patients with fibroscan score >14 
kPa, (7 died; 4 developed liver 
failure)  Fibroscan scores were higher in 
patients with a history of heavy 
alcohol use (23 ± 4.5 vs. 5.6 ± 0.3, P 
< 0.0001).  A single liver stiffness measurement 
was highly predictive of liver-related 
mortality 









Drug users on 
MMT 
(174) 
2010-2012 Retrospective prevalence 
study (log review)  
Anti-HCV 2010 = 6% 
Anti-HCV 2011=13% 
Anti-HCV 2012 = 24% 
 





Single site  




Chart audit of HCV 
screening measuring the 





(30) by a few 
months in 
2014 
effect of chart labelling (star) evidence of documentation of an 
HCV screen 
[60] 2016 










PWUD - Opioid 
users on MMT 
(358; 40% of 
eligible population; 






Audit of HCV screening 
using retrospective patient 
records  
 
Anti-HCV = 66% 









primary care for 
MMT (106) 
2015 Commentary (letter) 
 
Secondary analysis of data 
collected during a feasibility 
study of an alcohol brief 
intervention for patients 
attending primary care for 
MMT 
Anti-HCV = 51%  HCV tested = 99%  Self-reported HCV treatment = 19% 
 
Problem alcohol use = 45%  37% were anti-HCV and had problem 
alcohol use 
 
Patients’ knowledge of HCV care can best be 
optimised through community-based 
approaches to HCV treatment 
[58] Keegan et al 
2017 
Dublin 







January 2015  Cross sectional prevalence 
study (retrospective chart 
review) with associated risk 
factors 
Anti-HCV = 63.6 % with no significant 
gender difference (p=0.717)  
 
Significant risk factors for HCV infection 
(p<0.05):  age  age of first drug use   age of first injection   type of first drug used  early age of MMT entry   
 
Those with no IDU had decreased odds of 
being HCV positive by 91.1%. 
[59] 2017 












PWUD on MMT 





Audit; Retrospective chart 
review 
 
Anti-HCV = 79% 









Drug users on OST 
(133; m=81) 
2017 Cross-sectional  
Prevalence 
 
Anti-HCV = 77.2%  92.5% had been screened for HCV  14 (14.7%) patients previously 
diagnosed with HCV had ever 
initiated HCV treatment 
 
[9] 2017 




> 18 years  
(3795; m=1860) 
2014-2016 Anonymised and randomised 
laboratory analysis of 
residual serum samples at 
the NVRL 
 
Anti-HCV = 1.4% 
HCV RNA = 0.57% (95% CI: 0.40-0.81%)  higher in men (0.91%; 95% CI: 0.61-
1.4%)  east of the country (1.4%; 95%CI: 
0.99-2.0%)   0-39 years (1.1% (95% CI: 0.59-
2.0%)  40-49 years (1.1% (95% CI: 0.64-
1.9%)  Men born between 1965 and 1984 
from the east of the country have the 













Anti-HCV = 74%  High levels of comorbid illness 
al Hospital ED 
[19] 2016 
Carew et al  
 
National PWID registered on 
NDTRS 
(14320; m=10597) 
1991-2014 Mathematical modelling Number of PWID with HCV infection = 
12,423 (95% CI 10,799-13,161)  
 
Number of PWID with chronic HCV infection 
= 9,317 (95% CI 8,022-9,996) 
  Estimated number of new infections 
peaked in 1997.   By 2014, more than one quarter 
(27.0%) of PWIDs with chronic HCV 
infection were estimated to have been 
infected for 0–10 years, 43.4% for 
11–20 years, 22.8% for 21–30 years 












Table 3: Guidelines and policy  
 Date and author Setting Sample (n) Data 
collection 
Design  Main results 





reporting on HCV 
management guideline 
development for GPs 
of care of patients at risk of HCV, including  general and preventative care  care of other bloodborne and hepatotoxic 
viruses  factors to be considered and appropriate 
evaluation prior to referring a patient for 




Subgroup of the 
Blood Borne Virus 
Forum and the 
Eastern Regional 
Health Authority  
 
ERHA 16 workshops with 
service planners, health 





2004 A regional hepatitis C 
strategy document 













Dublin Prisoners  
 
- Guidelines  Provide prisoners   general health information  advice and testing  referral to appropriate specialist services 
in relation to HCV where clinically 




National   PWID & prisoners  2007 First national strategy  Reviewed and updated recommendation 
from the 2004 ERHA report.   Developed 36-point action plan 
Prioritising recommendations for 2011- 
2012 in the areas of HCV surveillance, 
education, prevention and treatment.  
[68] 2014 
DOH 
National HCV infected patients - Guidelines  Recommendations:  HSE establish a Hepatitis C Treatment 
Programme with a strong governance and 
management structure   Provide drug treatment to those with 
greatest clinical need as a priority and 
treat as many patients as possible with the 
available resources 
[69] HSE 2017 
 
National    OST Guidelines   All drug users (including non-PWID) 
should be screened for HCV.   Anti-HCV patients should be tested for 
HCV-antigen and LFTs  all antigen positive patients should be 
referred to specialist services for PCR, 
fibroscanning and consideration for 
treatment.   All patients at risk of HCV infection 
should be given information and advice 
on the disease and how it is transmitted.   IDU and alcohol misuse should not 
exclude patients from treatment.   Risks of concurrent alcohol use should be 







Table 4: Treatment outcomes (7 studies) 
 Date and 
author 
Setting Sample (n) Data 
collection 












(496; m= 341; 2 years 
follow up = 127) 
 
 














HCV RNA:  Negative = 38% (self-clearance) (f = 47.4 %; m = 
34.5%)  Follow up (2yrs) =   82.2% sustained viral 
clearance   Overall viral clearance = 31.1%  Genotype distribution (1 = 48.8%; 3 = 48.5%) 
[77] 2006 
Hopkins 
Single site  
Hospital  
Co-infected with HIV 
and HCV patients with 
CD4 counts >200 
cells/mL 






SVR = 53%  Genotype 2 and 3 patients had a significantly 


















chart review  
 
202/386 – referred to co-infected clinic, with 107 
completing treatment  SVR = 44% (similar outcomes for PWID 
compared to patients with other transmission risks) 
 
Associations with missed appointments  younger age  active IDU  advanced HIV infection 
 
Dedicated co-infection clinics lower the threshold for 












(repeat referrals = 742 




SVR = 74%  History of IDU was not a significant predictor of 
lower therapy completion rate or achievement of 
SVR 
 
In total, 451 (61%) dropouts occurred  141 (19%) failed to attend their initial appointment  180 dropped out from early outpatient management  29 failed to attend liver biopsy  81 defected from subsequent outpatient follow-up. 
 
Statistically significant associations with history of injection 
drug use  dropout immediately after the referral (P<0.001)  dropout from early outpatient management (P<0.001)   dropout over entire span of disease management 
(P<0.001)  
 














Anti-HCV = 33% at 10 yrs.  (survivors) 
Anti-HCV = 40% at 25 yrs.  (survivors)  63 % of the cohort had died by 2010, of which 26 
were attributed to HIV disease   Median survival time for those ant-HCV = 21 
years (95 % CI 15.5–26.5) which was significantly 
lower than the median survival time for drug users 







HCV infected patients 
(1000; Former PWID 
(>6 months) = 608; 
Recent PWID (<6 
months) = 85; 
Non-drug users = 307) 
2002-2012 Retrospective 
chart review 
SVR in PWID = 64.2%   No significant compared to non-PWID (60.9%) 
[RR = 1.05, 95% CI 0.95±1.17]  There was no significant difference in SVR rates 
between the groups controlling for genotype 
(48.4% vs 48.4% for genotype 1; 74.9 vs 73.3% 
for genotype 3).   No significant difference in treatment non-
adherence between the groups (8.4% in PWID vs 






Table 5: HCV-related health issues 
 Date and author Setting Sample (n) Data 
collection 
Design  Main results 
[81] 2001 









m=17; PWID = 25) 
 Cross-sectional  
Prevalence of 
rheumatological disease, 
anxiety and depression and 
relationship to mode of 
acquisition 
Anxiety and depression 
scores were significantly 
higher in IVDUs (P= 0.005) 
compared with controls. 
 
[84] 2005 










(90; m= 67; 47% 
PWID) 
 Prevalence of mood disorder 
and associated risks using a 
self-completed structured 
questionnaire 
Depressive disorders:   1-month prevalence = 
21% (72% previously 
undiagnosed)  Current MMT 
strongly associated 
with risk of 
depression (OR, 5.0; 
95% CI, 1.08–23.0).   After adjustment for 
age and sex, 
depression was 
associated with 
poorer work and 
social adjustment, 
lower acceptance of 
illness, higher illness 
stigma, poorer 
reported thinking and 
concentration, and 
higher levels of 
subjective physical 
symptoms (all P<.05)  
 
Anxiety disorders:  1-month prevalence = 
24% (86% previously 
undiagnosed)  Anxiety disorders 
were uncorrelated 
with any risk factor. 
 
[79] 2018 















2010-2018 Retrospective record audit 
 
Comparisons between 
community and prison 
populations 
SVR prison = 90.3%  
SVR community = 87.5% 
 










Table 6: Qualitative research reporting on patients’ and health providers’ experiences 
 Date and 
author 
Setting Sample (n) Data 
collection 
Design  Main results 
[43] 2005 


















  Follow up investigations for HCV =8  Treatment = 1  100% aware of HCV  22/25 consulted healthcare professional about 
HCV  21/25 knew HCV infection was caused by 
injecting  High awareness of harm reduction measures and 







Prison officers  Cross sectional 
survey 
 87% reported not knowing enough about these 
diseases to enable them to take the necessary 
precautions at work  Longer serving and senior officers were less 
fearful and less anxious about contracting the 
infections 
 Officers who had received hepatitis B 
vaccination were no less worried about hepatitis 
B than unvaccinated colleagues  Training on blood borne viruses had little effect 
on prison officers' knowledge or perception of 







HCV infected patients 
awaiting treatment 
(87; m=64; PWID = 
46%) 
 Prevalence of 
illness-related 




 Fear of disclosure combined with social 
isolation and social rejection  Stigma was higher in those in manual 
occupations and the unemployed than in those in 
non-manual occupation  High levels of disease-associated stigma in those 
with disease associated with IDU and iatrogenic 
disease caused by transfusion or anti-D blood 
products  Stigma was associated with depression (OR = 
1.4)   Stigma was also associated with poorer work 
and social adjustment, lower acceptance of 
illness, higher subjective levels of symptoms 
and greater subjective impairment of memory 
and concentration. These associations were 
replicated in the non-depressed subsample.   Strong link between stigma and well-being in 
hepatitis C 
[85] 2010 


















Anti-HCV = 91% 
HIV co-infected = 11% 
 
Barriers to HCV screening and treatment:    Perceptions of HCV infection as relatively 
benign  fear of investigations and treatment including 
liver biopsy and interferon 
ID clinic (1)  feeling well  limited knowledge of testing sites  not being referred for specialist investigations  ineligibility for treatment  competing priorities (employment, education, 
and addiction). 
 
Facilitators to HCV screening and treatment:     relationships with health care providers  trust in providers  concern for the service-user  continuity of care  education on HCV infection, investigations, and 
treatment  becoming symptomatic  responsibilities for children  wanting to move on from drug use 
 
[86] Whitaker 
et al 2011 
Dublin Drug using sex 
workers (35; m=4) 
 One-to-one in-depth 
interviews 
Multiple layers of stigma were reported, linked to sex 
work, drug use (including IDU) and having contracted 
HIV or HCV   Stigma was powerfully reinforced by the 
language routinely used by health professionals.   To improve the effectiveness of harm-reduction 
interventions, it is recommended that service 
providers change their language, in particular in 
recognition of the human dignity of these 
clients, but also to help attract and retain drug 
users in services, and to help reduce the 


















Attendance = 90%  high levels of unemployment (90%) and 
homelessness (40%)  higher fibroscan scores (>8.5Kpa) were 
associated with longer time since diagnosis (p= 
0.016).  
 
Patient identified barriers to engagement:  alcohol and drug use  fear of HCV treatment and liver biopsy  imprisonment  distance to hospital  early morning appointments. 
 
Patient identified enablers:  afternoon appointments  enhanced prison referral mechanisms into the 
community Fibroscan unit  location of services within the addiction 











hostels, GPs  
Study sites: 
 
Pilot sites (4): 2 
Dublin based 
community drug 
treatment centres, 1 




10 interviewees from 
8 sites at baseline. 
6 participants in pilot 





Estimated HCV prevalence in GP practices = 1-10% 
 
Estimated chronic prevalence in pilot sites = 15-75% 
  PWID were identified as the main group facing 
barriers to accessing specialist HCV care.   State-employed doctors and nurses were 
successfully recruited to participate in the 
project.   GPs did not participate, due mainly to a lack of 
time and the absence of reimbursement for 
participation.   Benefits to practitioners and their patients were 
reported. Participants expressed interest in 
completion continued engagement with similar 
multidisciplinary, multisite educational 
interventions in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
